Journals / Journal of Microbiology and Infectious Diseases / 2014 / Cilt: 4 - Sayı: 4

Predictive values of serum amyloid-A and CRP for infection in febrile neutropenic cancer patients

Febril nötropenik kanser hastalarında serum amiloid-A and C-reaktif protein CRP'nin enfeksiyon için öngörü değeri

Pages
128–135
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

SAA and CRP levels on the last day of FEN course were significant for infection and mortality (for infection: p=0.003 for CRP and p=0.026 for SAA; for mortality: p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To evaluate predictive values of serum amyloid A (SAA) and C-reactive protein (CRP) for infection and mortality in patients with febrile neutropenia (FEN).
📊
Key Findings & Data:Results: Sixty-five FEN episodes of 52 patients were evaluated.
💡
Conclusion & Impact:SAA and CRP levels on the last day of FEN course were significant for infection and mortality (for infection: p=0.003 for CRP and p=0.026 for SAA; for mortality: p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To evaluate predictive values of serum amyloid A (SAA) and C-reactive protein (CRP) for infection and mortality in patients with febrile neutropenia (FEN). Methods: Daily measurement of serum SAA and CRP levels of patients during antibiotherapy for FEN. Results: Sixty-five FEN episodes of 52 patients were evaluated. Median CRP and SAA levels on 1st day of FEN were 137 mg/L (23-420 mg/L) and 547 mg/L (11-1660 mg/L), respectively. For detection of infection of infection the sensitivity, positive predictive value (PPV), and negative predictive value (NPV) of SAA at a level of >80 mg/L were as 100%, 48% and 100%. Whilethe sensitivity, PPV, and NPV of CRP at a level of >50mg/L were as 86%, 47% and 60%, respectively. Predictive values of initial SAA and CRP levels for infection didn't differ significantly (CRP: p=0.24, SAA: p=0.39). SAA and CRP levels on the last day of FEN course were significant for infection and mortality (for infection: p=0.003 for CRP and p=0.026 for SAA; for mortality: p

Özet

Amaç: Febril nötropeni (FEN)si olan hastalarda serum amyloid A (SAA) ve C-reaktif protein (CRP)'in enfeksiyonun erken tanısı ve mortaliteyi öngörmede değerini incelemek Yöntemler: Antibiyoterapi sırasında hastaların serum SAA ve CRP düzeyleri günlük olarak ölçüldü. Bulgular: Elli-iki hastanın 65 FEN atağı incelendi. FEN tablosunun ilk günündeki medyan CRP ve SAA değerleri sırasıyla 137 mg/L (23-420 mg/L) ve 547 mg/L (11-1660 mg/L) idi. Enfeksiyonun tespitinde 80 mg/L üzerindeki SAA düzeyinin duyarlılığı 100%, pozitif prediktif değeri (PPD) ve negatif (NPD) prediktif değerleri sırasıyla %48 ve %100 idi. Enfeksiyonun tespitinde 50 mg/L üzerindeki CRP düzeyinin duyarlılığı %86, PPD ve NPD sırasıyla %47 ve %60 idi. Başlangıç SAA ve CRP düzeyleri arasında infeksiyonu öngörmede anlamlı fark saptanmadı (CRP için p=0,24, SAA için p=0,39). Ayrıca, febril atağın ilk gününden onikinci gününe kadarki günlük medyan SAA ve CRP değerleri arasında istatistiksel anlamlı bir korelasyon vardı (p

🔖

Cite This Article

BATIREL, A., ÖZER, S., SALEPCİ, T., GENCER, S. (2022). Predictive values of serum amyloid-A and CRP for infection in febrile neutropenic cancer patients. Journal of Microbiology and Infectious Diseases, Cilt: 4 - Sayı: 4, 128–135. https://ajindex.com/articles/564449

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Quadri TL, Brown AE. Infectious complications in the critically ill patient with cancer. Semin Oncol 2000;27:335-346
  2. Ellis M. Febrile neutropenia. Ann N Y Acad Sci 2008;1138:329- 350
  3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56-e93
  4. Sudhoff T, Giagounidis A, Karthaus M. Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice. Chemotherapy 2000;46:77-85
  5. Lehrnbecher T, Venzon D, de Haas M, et al. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis 1999;29:414-419
  6. Engel A, Steinbach G, Kern P, Kern WV. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 1999;31:185-189
  7. Kern WV, Heiss M, Steinbach G. Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis 2001;32:832-835
  8. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, et al. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 2001;32:1718-1725
  9. Uys A, Rapoport BL, Fickl H, et al. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer riskindex score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl) 2007;16:475-483
  10. Persson L, Soderquist B, Engervall P, et al. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 2005;74:297-303
  11. Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009;32:471-482
  12. Kanoh Y, Abe T, Masuda N, Akahoshi T. Progression of nonsmall cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A. Oncol Rep 2013;29:469-473
  13. Eklund KK, Niemi K, Kovanen PT. Im